First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study

Figures & data

Table 1. Incident inflammatory bowel disease (IBD) cases per year from 2010 to 2016 stratified by diagnosis.

Year of diagnosis	Crohn’s disease, n (%)	Ulcerative colitis, n (%)
Total	5283 (36)	9362 (64)
2010	753 (36)	1361 (64)
2011	788 (36)	1405 (64)
2012	746 (38)	1234 (62)
2013	781 (38)	1299 (62)
2014	720 (36)	1264 (64)
2015	752 (35)	1414 (65)
2016	743 (35)	1385 (65)

Table 2. Proportion of patients initiating biologics within 12 months after diagnosis stratified by year of diagnosis.

Cohort	Crohn’s disease, n (%)	Ulcerative colitis, n (%)
Total	1324 (25)	845 (9)
2010	130 (17)	93 (7)
2011	153 (20)	94 (7)
2012	178 (24)	101 (8)
2013	214 (28)	102 (8)
2014	185 (26)	119 (9)
2015	225 (30)	161 (11)
2016	239 (33)	175 (13)

Figure 1. (a) Kaplan–Meier failure estimate of time from diagnosis to first biologic stratified by year of diagnosis for CD patients. The Y axis shows the cumulative probability of initiating biologics. The X axis shows development over time in months. (b) Kaplan–Meier failure estimate of time from diagnosis to first biologic stratified by year of diagnosis for UC patients. The Y axis shows the cumulative probability of initiating biologics. The X axis shows development over time in months.

Table 3. The use of first-line biologics stratified by diagnosis and year of diagnosis.

Diagnosis	Cohort	Adalimumab	Golimumab	Infliximab	Vedolizumab
Crohn’s disease	Total	471 (36)	3 (0)	848 (64)	2 (0)
	2010	58 (45)	1 (1)	71 (55)	0 (0)
	2011	80 (52)	0 (0)	73 (48)	0 (0)
	2012	100 (56)	0 (0)	78 (44)	0 (0)
	2013	115 (54)	0 (0)	99 (46)	0 (0)
	2014	57 (31)	2 (1)	126 (68)	0 (0)
	2015	30 (13)	0 (0)	195 (87)	0 (0)
	2016	31 (13)	0 (0)	206 (86)	2 (1)
Ulcerative colitis	Total	127 (15)	22 (3)	689 (82)	5 (1)
	2010	7 (8)	0 (0)	85 (91)	0 (0)
	2011	19 (20)	0 (0)	75 (80)	0 (0)
	2012	39 (39)	2 (2)	60 (59)	0 (0)
	2013	32 (31)	3 (3)	67 (66)	0 (0)
	2014	15 (13)	5 (4)	99 (83)	0 (0)
	2015	12 (7)	7 (4)	142 (88)	0 (0)
	2016	3 (2)	5 (3)	161 (92)	5 (3)

Numbers are listed as n (%, rounded). Patients that received biologic therapy for other diagnoses before their IBD diagnosis (n = 102) were excluded as new treatment cases and were removed from further analysis. Concurrent use of two different biologics at the first biologic registration was interpreted as a coding error for 12 patients, and these patients were assigned to a biologic group based on their following biologic registrations (Table S1, Supplementary).

Figure 2. (a) First-line biologic for CD patients initiating biologics stratified by infliximab and adalimumab as first biologic registration. Y axis shows percent of biologic recipients started on either infliximab or adalimumab. X axis shows yearly cohorts from 2010 to 2016. (b) First-line biologic for UC patients initiating biologics stratified by infliximab and adalimumab as first biologic registration. Y axis shows percent of biologic recipients started on either infliximab or adalimumab. X axis shows yearly cohorts from 2010 to 2016.

Data availability statement

The data underlying this article were provided by the Norwegian National patient register (NPR) and the Norwegian Prescription Database (Nor-PD) by permission. Data cannot be shared publicly due to the privacy of the patients listed in the registries. Data are available from the NPR (https://www.helsedirektoratet.no/tema/statistikk-registre-og-rapporter/helsedata-og-helseregistre/norsk-pasientregister-npr) and Nor-PD (http://www.reseptregisteret.no/) through an application process.